| 摘要 |
The use in the of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent in the manufacture of a medicament for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal. Examples of insulin secretagogues include glibenclamide, glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide, glycylamide or repaglinide. Examples of biguanide antihyperglycaemic agents are metformin, buformin and phenformin. Suitable insulin sensitisers include 5 - [4- [2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl]thiazolidine-2,4- dione, (+) -5-[[4-[(3,4- dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H- 1 -benzopyran-2- yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1- methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone).
|
